Mirum Q1 revenue $111.6M; raises 2025 guidance to $435-450M

Mirum Pharmaceuticals, Inc.

2025-Q1 EPS reported -$0.30 revenue$111,585,000

Q1 2025 total revenue $111.6M vs $69.2M YoY, driven by LIVMARLI ($73.2M, +71%) and Bile Acid Medicines ($38.4M, +47%).
Raises full-year 2025 revenue guidance to $435-450M from prior range.
LIVMARLI oral tablet formulation approved by FDA; also approved in Japan for ALGS and PFIC.
VISTAS PSC study enrollment completion expected Q3 2025; topline data Q2 2026.
Cash and investments $298.6M as of March 31, 2025, up from $292.8M at year-end 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.